Search hospitals > Pennsylvania > Sayre
Guthrie Medical Group PC-Robert Packer Hospital
Claim this profileSayre, Pennsylvania 18840
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
137 reported clinical trials
6 medical researchers
Summary
Guthrie Medical Group PC-Robert Packer Hospital is a medical facility located in Sayre, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Guthrie Medical Group PC-Robert Packer Hospital is involved with conducting 137 clinical trials across 224 conditions. There are 6 research doctors associated with this hospital, such as Joyson Poulose, Philip A. Lowry, Thomas J. Gergel, and Vineela Kasireddy.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Joyson PouloseGuthrie Medical Group PC-Robert Packer Hospital5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
26 reported clinical trials
67 drugs studied
Philip A. LowryGuthrie Medical Group PC-Robert Packer Hospital6 years of reported clinical research
Studies Lung Cancer
Studies Breast Cancer
17 reported clinical trials
61 drugs studied
Thomas J. GergelGuthrie Medical Group PC-Robert Packer Hospital6 years of reported clinical research
Studies Lung Cancer
Studies Breast Cancer
6 reported clinical trials
20 drugs studied
Vineela KasireddyGuthrie Medical Group PC-Robert Packer Hospital5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
6 drugs studied
Clinical Trials running at Guthrie Medical Group PC-Robert Packer Hospital
Lung Cancer
Breast Cancer
Breast cancer
Cancer
Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Cutaneous Melanoma
Prostate Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Guthrie Medical Group PC-Robert Packer Hospital?
Guthrie Medical Group PC-Robert Packer Hospital is a medical facility located in Sayre, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Guthrie Medical Group PC-Robert Packer Hospital is involved with conducting 137 clinical trials across 224 conditions. There are 6 research doctors associated with this hospital, such as Joyson Poulose, Philip A. Lowry, Thomas J. Gergel, and Vineela Kasireddy.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.